10-Q quarterly report · filed Nov 4, 2026

Arcus Biosciences, Inc. (RCUS) Q3 2026 10-Q Quarterly Report

Short answer

Arcus Biosciences, Inc. (RCUS) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $3M (down 50.0% year over year) with net income of −$128M.

Q3 2026 key financials · XBRL

Revenue
$3M
−50.0% YoY · −90.9% QoQ
Net income
−$128M
+5.2% YoY · −40.7% QoQ
Operating margin
-4366.7%
EPS (diluted)
−$1.00
+23.1% YoY · −38.9% QoQ

Source: XBRL data from the Arcus Biosciences, Inc. (RCUS) Q3 2026 10-Q on SEC EDGAR. USD.

Arcus Biosciences, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue decline, exact quarterly dollar amounts obscured in filing table, down 65% YoY overall
  • Net loss $128M vs $135M YoY, operating loss $131M vs $142M
  • Best program: casdatifan plus cabozantinib, median PFS 14.5 months and cORR 44%
  • Worst program: domvanalimab, PACIFIC-8 Phase 3 discontinued in August 2026
  • Operating cash use $345M vs $362M, October equity offering gross proceeds approximately $288M, runway into 2029

Risk Factors

  • Newly triggered compliance risk: U.S. BIOSECURE Act enacted December 2025 could restrict sole zimberelimab manufacturer WuXi Biologics
  • Most material operational update: etrumadenant development paused in third-line metastatic colorectal cancer to prioritize late-stage programs
  • Regulatory risk: FDA disruptions from funding shortages, staffing limitations, and policy changes could delay reviews and approvals
  • Competitive risk: Phase 3 STAR-221 discontinued after December 2025 interim analysis showed no benefit versus standard of care
  • Financial risk: $694 million cash, equivalents, and marketable securities funds planned operations into 2029; additional capital may still be required

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Arcus Biosciences, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.